In addition, CCT3 downregulation could sensitize lung adenocarcinoma cells to cisplatin by inhibiting the Janus kinase 2/signal transducer and activator of the transcription 3 (JAK2/STAT3) pathway. Here, JAK2 is linked to lung adenocarcinoma.